Following an internal investigation, the McKesson (MCK) board absolved senior management of any failures to oversee the distribution of opioid painkillers, an issue that has haunted several wholesalers as the opioid crisis in the U.S. worsens.
Notably, the probe found that senior managers “worked in earnest” to meet Drug Enforcement Agency requirements, such as reporting suspicious orders to pharmacies, and had oversight procedures in place for a monitoring program and distribution facilities.
Consequently, the board declared McKesson executives acted in “good faith” to meet the obligations of a 2008 settlement with the DEA, which was reached because the wholesaler failed to report suspicious orders, according to this statement. As part of the deal, McKesson paid $13 million to resolve the civil charges.
About the Author Reprints
